AstraZeneca Addresses CEO Speculation Amid Share Drop
AstraZeneca sought to downplay speculation about its CEO, Pascal Soriot, leaving the company after its shares dropped over 4% following a report in a British tabloid. The company initially declined to comment but later issued a statement saying they do not comment on market rumors. AstraZeneca shares closed down 3.2% after touching their lowest point since July. Analysts and a shareholder attributed the drop to the report, though its accuracy could not be independently verified. Another article in The Times, which focused on the retirement of a senior executive, may have also affected the shares.